Q-omics provides the consensus-scored CLUAP1 profile across patient tissues and cancer cell-line models. CLUAP1 expression is associated with patient survival in 20 of 34 cancer types, with the highest sampling consensus in KIRC. Among the 18 cancer types available for tumor–normal comparison, CLUAP1 is differentially expressed in 11, with the highest sampling consensus in KIRP. Additionally, CLUAP1 protein abundance shows 21,320 significant protein co-abundance associations, with the highest sampling consensus in LUAD. Together, these results highlight KIRC, KIRP, and LUAD as cancer lineages where CLUAP1 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for CLUAP1 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes CLUAP1 survival associations across molecular data types. CLUAP1 RNA expression shows survival associations in the most cancer types (20), followed by mutation status (4) and mass-spec protein abundance (9). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible CLUAP1 RNA expression–survival associations across cancer types. High CLUAP1 expression shows unfavorable associations in SCLC, ACC and LIHC, but favorable associations in KIRC, UCEC and BRCA. The KIRC Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p < 0.001). Together, the overview and detailed table identify KIRC as the clearest survival context for CLUAP1 RNA expression.
This table summarizes CLUAP1 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 11, while mass-spec protein shows differences in 9. The strongest signals are observed in KIRP for RNA and LUAD for protein.
This table ranks reproducible tumor–normal expression differences for CLUAP1. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. CLUAP1 shows lower tumor expression in KICH, BLCA, THCA and UCEC and higher tumor expression in KIRP and LIHC. The KIRP box plot shows higher CLUAP1 RNA expression in tumor versus normal tissue (log2 FC = +0.803, t-test p < 0.001).
This table shows molecular features associated with CLUAP1 in patient tissues and cancer cell lines. In patient samples, CLUAP1 shows the broadest associations at the RNA and protein expression levels, with LUAD recurring as the lineage with the largest associated feature set. In cancer cell lines, CLUAP1 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in CNS, while CRISPR and shRNA rows add functional-dependency signals in BONE and LARGE_INTESTINE.
